Institution
Tufts Center for the Study of Drug Development
About: Tufts Center for the Study of Drug Development is a based out in . It is known for research contribution in the topics: Drug development & Clinical trial. The organization has 78 authors who have published 258 publications receiving 16047 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The results indicate that the start- up process is on average 5 to 6 months in total duration, and cycle times across all activities, including site identification, site selection, and study start-up, are faster for repeat sites than for new sites.
Abstract: Background:Site identification, site selection, and study start-up have become the focus of improvement by organizations conducting clinical trials.Methods:To examine and measure the process from site identification through site activation, Tufts Center for the Study of Drug Development (CSDD) conducted a comprehensive survey among pharmaceutical organizations, biotech companies, and contract research organizations (CROs). Responses from over 400 unique companies were gathered and analyzed.Results:The results indicate that the start-up process is on average 5 to 6 months in total duration, and cycle times across all activities, including site identification, site selection, and study start-up, are faster for repeat sites than for new sites. Comparisons between sponsor and CROs indicate that CROs completed all site-related activities 6 to 11 weeks faster than sponsors. Other areas impacting cycle times were examined, including centralized versus decentralized functions, investment in technology, and organi...
11 citations
•
11 citations
••
TL;DR: To determine phase transition probabilities and approval success rates for recombinant protein (rDNA) therapeutics, the Tufts Center for the Study of Drug Development collected data for 271 rDNA therapeutics that entered clinical study between 1980 and 2002.
Abstract: Only a small subset of the therapeutics that enter clinical studies will prove to be safe and effective in humans and gain approval for marketing. The success of the products and, by inference, the sponsoring companies can be measured by tracking advancement through the clinical phase and review transitions to marketing approval. To determine phase transition probabilities and approval success rates for recombinant protein (rDNA) therapeutics, the Tufts Center for the Study of Drug Development collected data for 271 rDNA therapeutics that entered clinical study between 1980 and 2002. The data were stratified into eight therapeutic categories. Approval success rates were calculated for rDNA therapeutics with two possible fates: (i) approval in any country and (ii) U.S. approval only. Global approval success rates ranged from 23% to 63%, and U.S. approval success rates ranged from 17% to 58%. Trends in clinical phase lengths over five time periods and an overview of the rDNA therapeutics currently under Food and Drug Administration review are discussed.
10 citations
•
10 citations
••
TL;DR: Data on the entry rates of second and later entrants in 43 pharmacologic classes, as well as the timing of patent filings and development milestones for 79 later‐in‐class drugs, found that a substantial majority of later-in‐ class drugs had a patent filed and were in clinical development prior to the approval of the first‐in-class drug.
Abstract: We examined data on the entry rates of second and later entrants in 43 pharmacologic classes, as well as the timing of patent filings and development milestones for 79 later-in-class drugs. The median time to when a second entrant was approved was 2.7 years. A substantial majority of later-in-class drugs had a patent filed and were in clinical development prior to the approval of the first-in-class drug.
10 citations
Authors
Showing all 78 results
Name | H-index | Papers | Citations |
---|---|---|---|
Henry G. Grabowski | 44 | 117 | 12868 |
Janice M. Reichert | 44 | 94 | 9253 |
Jeffrey S. Brown | 42 | 161 | 6312 |
Toben F. Nelson | 40 | 136 | 9539 |
Francisco J. de Abajo | 33 | 97 | 4181 |
Joseph A. DiMasi | 31 | 76 | 11513 |
Kenneth I. Kaitin | 28 | 92 | 2518 |
Kenneth A. Getz | 20 | 97 | 2428 |
Joshua Cohen | 19 | 63 | 927 |
Andrew W. Wilson | 18 | 40 | 2977 |
Christopher-Paul Milne | 13 | 44 | 494 |
Michael Manocchia | 12 | 17 | 1090 |
Ronald P. Evens | 11 | 21 | 312 |
Cherie Paquette | 11 | 32 | 627 |
Stella Stergiopoulos | 9 | 18 | 211 |